2,3-dihydroxy-9,10-dimethoxy-13-n-octylprotoberberine chloride | 1375475-63-0

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 原小檗碱生物碱及其衍生物
• 英文名称: 2,3-dihydroxy-9,10-dimethoxy-13-n-octylprotoberberine chloride
• 英文别名: 9,10-Dimethoxy-13-octyl-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-2,3-diol;chloride
• CAS: 1375475-63-0
• 化学式: C₂₇H₃₄NO₄*Cl
• 分子量: 472.024
• InChiKey: XUTJBWITPSBWIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.69
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  62.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,3-dihydroxy-9,10-dimethoxy-13-n-octylprotoberberine chloride 、 1-碘代丙烷 在 potassium hydroxide 、 盐酸 作用下， 以 N,N-二甲基甲酰胺 、 水 为溶剂， 以43%的产率得到2,3-di-n-propoxy-9,10-dimethoxy-13-n-octylprotoberberine chloride
  参考文献：
  名称：

  Synthesis, structure–activity relationship and in vitro anti-mycobacterial evaluation of 13-n-octylberberine derivatives

  摘要：

  Twenty-eight new 13-n-octylberberine derivatives were synthesized and evaluated for their activities against drug-susceptible Mycobacterium tuberculosis (M. tuberculosis) strain H(37)Rv. Among these compounds, compound 16e was the most effective anti-tubercular agent with a MIC value of 0.125 mu g/mL Importantly, compound 16e exhibited more potent effect against rifampicin (RIF)- and isoniazid (INH)-resistant M. tuberculosis strains than both RIF and INN, suggesting a new mechanism of action. Therefore, it has been selected as a drug candidate for further investigation, or as a chemical probe for identifying protein target and studying tuberculosis biology. We consider 13-n-octylberberine analogs to be a promising novel class of antituberculars against multi-drug-resistant (MDR) strains of M. tuberculosis. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.03.012
• 作为产物：
  描述：

  盐酸小檗碱 在 sodium tetrahydroborate 、 间苯三酚 、 硫酸 、 potassium carbonate 、 溶剂黄146 、 sodium hydroxide 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 7.5h， 生成 2,3-dihydroxy-9,10-dimethoxy-13-n-octylprotoberberine chloride
  参考文献：
  名称：

  Synthesis, structure–activity relationship and in vitro anti-mycobacterial evaluation of 13-n-octylberberine derivatives

  摘要：

  Twenty-eight new 13-n-octylberberine derivatives were synthesized and evaluated for their activities against drug-susceptible Mycobacterium tuberculosis (M. tuberculosis) strain H(37)Rv. Among these compounds, compound 16e was the most effective anti-tubercular agent with a MIC value of 0.125 mu g/mL Importantly, compound 16e exhibited more potent effect against rifampicin (RIF)- and isoniazid (INH)-resistant M. tuberculosis strains than both RIF and INN, suggesting a new mechanism of action. Therefore, it has been selected as a drug candidate for further investigation, or as a chemical probe for identifying protein target and studying tuberculosis biology. We consider 13-n-octylberberine analogs to be a promising novel class of antituberculars against multi-drug-resistant (MDR) strains of M. tuberculosis. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.03.012

文献信息

• Synthesis, structure–activity relationship and in vitro anti-mycobacterial evaluation of 13-n-octylberberine derivatives
  作者：Yan-Xin Liu、Chun-Ling Xiao、Yan-Xiang Wang、Ying-Hong Li、Yan-Hui Yang、Yang-Biao Li、Chong-Wen Bi、Li-Mei Gao、Jian-Dong Jiang、Dan-Qing Song

  DOI：10.1016/j.ejmech.2012.03.012

  日期：2012.6

  Twenty-eight new 13-n-octylberberine derivatives were synthesized and evaluated for their activities against drug-susceptible Mycobacterium tuberculosis (M. tuberculosis) strain H(37)Rv. Among these compounds, compound 16e was the most effective anti-tubercular agent with a MIC value of 0.125 mu g/mL Importantly, compound 16e exhibited more potent effect against rifampicin (RIF)- and isoniazid (INH)-resistant M. tuberculosis strains than both RIF and INN, suggesting a new mechanism of action. Therefore, it has been selected as a drug candidate for further investigation, or as a chemical probe for identifying protein target and studying tuberculosis biology. We consider 13-n-octylberberine analogs to be a promising novel class of antituberculars against multi-drug-resistant (MDR) strains of M. tuberculosis. (C) 2012 Elsevier Masson SAS. All rights reserved.